By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11025 Roselle Street
Suite 200
San Diego  California  92121  U.S.A.
Phone: 858-587-5870 Fax: 858-587-5871


Company News
bioTheranostics Release: Lifetime’s “The Balancing Act” Show For Women To Discuss The Breast Cancer Index Molecular Test 2/23/2015 11:08:02 AM
bioTheranostics Appoints Key Executives To Leadership Team 1/9/2015 9:28:41 AM
Studies Reinforce Unique Predictive And Prognostic Abilities Of bioTheranostics’ Breast Cancer Index Molecular Test 12/9/2014 1:32:09 PM
bioTheranostics Awarded Medicare Coverage for Breast Cancer Index℠ Molecular Test 10/15/2014 10:42:31 AM
bioTheranostics Appoints Nicolas Barthelemy As President And CEO 10/6/2014 8:04:52 AM
Study Shows Use Of 20/20 GeneSystems, Inc.’ Breast Cancer Indexsm Molecular Test Substantially Lowers Medical Costs For ER+ Breast Cancer Patients Compared With Standard Management 9/11/2014 10:07:53 AM
bioTheranostics Announces Update To Its bioT3 Metastatic Cancer Solution 8/12/2014 8:26:37 AM
bioTheranostics Names Ramesh Hariharan As Vice President Of Marketing 7/23/2014 12:12:05 PM
bioTheranostics Receives Approval To Perform Breast Cancer Index Testing For Patients In State Of New York 7/16/2014 10:29:02 AM
bioTheranostics’ Cancertype ID® Molecular Test Is A Cost-Effective Approach To Standardizing Diagnosis & Improving Metastatic Cancer Care, Study Shows 7/14/2014 6:33:02 AM